Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 8/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 6/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259578 | 1.00 | MET (0.53) | METFGFR1FGFR2FGFR3AXL | |
| SCHEMBL259579 | 1.00 | MET (0.53) | METFGFR1FGFR2FGFR3AXL | |
| SCHEMBL259577 | 1.00 | MET (0.53) | METFGFR1FGFR2FGFR3AXL | |
| SCHEMBL259884 | 0.84 | FGFR1 (0.72) | METFGFR1FGFR2FGFR3AXL | |
| SCHEMBL259883 | 0.84 | FGFR1 (0.72) | METFGFR1FGFR2FGFR3AXL | |
| SCHEMBL1224774 | 0.84 | MET (0.76) | METFGFR1FGFR2FGFR3AXL | |
| SCHEMBL1224768 | 0.84 | MET (0.76) | METFGFR1FGFR2FGFR3AXL | |
| SCHEMBL1226083 | 0.84 | MET (0.76) | METFGFR1FGFR2FGFR3AXL | |
| SCHEMBL1224771 | 0.84 | MET (0.76) | METFGFR1FGFR2FGFR3AXL | |
| SCHEMBL1224233 | 0.84 | MET (0.55) | METFGFR1FGFR2FGFR3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653073-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-02-18 | — | — | US | disclosed |
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2013-12-12 | — | — | US | disclosed |
| US-8541412-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-09-24 | — | — | US | disclosed |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP11B1, SDHA, CYP11B2 | MET 2084/4885FGFR1 875/4885FGFR2 2322/4885 |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | MET 2084/4885FGFR1 875/4885FGFR2 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.